Übersetzung für "Leiomyosarcoma" in Deutsch

Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Fortunately, only 10 percent of dogs have the malignant form of leiomyosarcoma.

The effects of Yondelis were also studied in one main study involving 266 patients with liposarcoma (a sarcoma originating in fat cells) or leiomyosarcoma (a sarcoma originating in ‘ smooth’ or involuntary muscle cells) that was advanced or metastatic (had spread to other parts of the body).

Additional efficacy data are available from a randomized active-controlled phase III study of trabectedin vs. dacarbazine (Study ET743-SAR-3007), in patients treated for unresectable or metastatic lipo- or leiomyosarcoma who have been previously treated with at least an anthracycline and ifosfamide containing regimen, or an anthracycline containing regimen and one additional cytotoxic chemotherapy regimen.

More than 25 different soft tissue sarcoma subtypes were represented in this trial, the most frequent being leiomyosarcoma (38.4 %), undifferentiated pleomorphic sarcoma (18.1 %) and liposarcoma (17.3 %).

The main analysis was performed in the following two subgroups: Leiomyosarcoma (LMS) and non-LMS (other).

These trials evaluated a total of 100 patients with lipo- and leiomyosarcoma and 83 patients with other types of sarcoma.

The efficacy and safety of trabectedin is based in a randomised trial in patients with locally advanced or metastatic liposarcoma or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide.

These trials evaluated a total of 100 patients with lipo and leiomyosarcoma and 83 patients with other types of sarcoma.

The efficacy and safety of trabectedin in soft tissue sarcoma is based in a randomised trial in patients with locally advanced or metastatic lipo- or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide.

The patients in this study (n=452) had locally recurrent, inoperable and/or metastatic soft tissue sarcoma of one of two subtypes – leiomyosarcoma or liposarcoma.

For soft-tissue sarcoma, Yondelis has been studied in one main study involving 266 patients with liposarcoma (a sarcoma originating in fat cells) or leiomyosarcoma (a sarcoma originating in ‘smooth’ or involuntary muscle cells) that was advanced or metastatic (had spread to other parts of the body).

Randomisation was stratified by PDGFR-? expression (positive versus negative), number of previous lines of treatment (0 versus 1 or more lines), histological tumour type (leiomyosarcoma, synovial sarcoma, and others) and ECOG performance status (0 or 1 versus 2).

There was no difference in efficacy between eribulin and dacarbazine in patients with advanced or metastatic leiomyosarcoma.

Tumor cells which can be detected with the present invention are, in particular, tumor cells from metastases, preferably micrometastases, from malignant tumors, especially cells from metastasizing tumors and/or neoplasms which are derived, for example, from a T-cell lymphoblastoma, T-cell leukemia cells, chronic myeloid leukemia cells, acute lymphatic leukemia cells, chronic lymphatic leukemia cells, teratocarcinoma, melanoma, carcinoma of the lung, large bowel cancer, breast cancer, hepatocellular carcinoma, kidney tumor, adrenal tumor, prostate carcinoma, neuroblastoma, brain tumor, small-cell carcinoma of the lung, rhabdomyosarcoma, leiomyosarcoma and/or lymphoma.

The compound for use according to claim 26, wherein the disease or disorder is sarcoma and the sarcoma is Askin?s tumor, sarcoma botryoides, chondrosarcoma, Ewing?s sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, hemangiosarcoma, Kaposi?s sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.

Other tumor types include fibrosarcoma (a malignant tumor derived from fibrous connective tissue), leiomyosarcoma (a cancer of the smooth muscle cells), and squamous cell carcinoma (a malignant tumor of skin cells).

Histological examination showed 11 rhabdomyosarcoma, 7 tumours of the paranasal sinus and nasal cavity, 1 leiomyosarcoma, 1 osteosarcoma, 1 spindle cell carcinoma, 1 basal cell carcinoma, 1 metastasis, 1 meningeoma and 1 inverted papilloma.

Leiomyosarcoma is an uncommon cancerous tumor, which, in this case, arises from the smooth muscles of the stomach and intestines.

The most common primary malignant bone tumor is osteosarcoma, followed by chondrosarcoma and Ewing sarcoma, while the most common soft tissue sarcoma is undifferentiated sarcoma, followed by liposarcoma and leiomyosarcoma.

Contrary to the relatively common benign bone and soft tissue tumors, bone and soft tissue sarcomas are rare malignancies. The most common primary malignant bone tumor is osteosarcoma, followed by chondrosarcoma and Ewing sarcoma, while the most common soft tissue sarcoma is undifferentiated sarcoma, followed by liposarcoma and leiomyosarcoma.

I would outpace and assure at least three leiomyosarcomas monozygotic of subs.

This means that leiomyosarcomas can start anywhere in the body.

Atropine is a southeast printed {59} intraatrial for order generic accutane in leiomyosarcomas up to 6 vehicles of dea and antidepressives with affair strabismus.

Tumors of the gastrointestinal tract are mostly intestinal lymphomas, adenocarcinomas, leiomyomas, leiomyosarcomas, and gastrointestinal stromal tumors (GIST).

They may be carcinoids, especially in the appendix and the small intestine, leiomyosarcomas and gastrointestinal stromal tumors (GISTs) which derive from the smooth muscle and/or the connective tissue of the intestinal mucosa.